How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment

Abstract

Background Debate over the viability of the current commercial research and development (R&D) model is ongoing. A controversial theme is the cost of bringing a new molecular entity (NME) to market. Objective Our aim was to evaluate the range and suitability of published R&D cost estimates as to the degree to which they represent the actual costs of industry. Methods We provided a systematic literature review based on articles found in the Pubmed, Embase and EconLit electronic databases, and in a previously published review. Articles published before March 2020 that estimated the total R&D costs were included (22 articles with 45 unique cost estimates). We included only literature in which the methods used to collect the information and to estimate the R&D costs were clearly described; therefore, three reports were excluded. We extracted average pre-launch R&D costs per NME and converted the values to 2019 US dollars (US$) using the gross domestic product (GDP) price deflator. We appraised the suitability of the R&D estimated costs by using a scoring system that captures three domains: (1) how success rates and development time used for cost estimation were obtained; (2) whether the study considered potential sources contributing to the variation in R&D costs; and (3) what the components of the cost estimation were. Results Estimates of total average capitalized pre-launch R&D costs varied widely, ranging from $161 million to $4.54 billion (2019 US$). Therapeutic area-specific estimates were highest for anticancer drugs (between $944 million and $4.54 billion). Our analysis identified a trend of increasing R&D costs per NME over time but did not reveal a relation between cost estimates and study ranking when the suitability scores were assessed. We found no evidence of an increase in suitability scores over time. Conclusion There is no universally correct answer regarding how much it costs, on average, to research and develop an NME. Future studies should explicitly address previously neglected variables, which likely explain some variability in estimates, and consider the trade-off between the transparency and public accessibility of data and their specificity. Use of our proposed suitability scoring system may assist in addressing such issues.

Value drivers of development stage biopharma companies

“…Crucial to this dispute are the costs associated with developing new drugs [3]. While scholars previously estimated research and development (R&D) costs of the internal drug development process [4][5][6], little is known about the value and costs associated with externally developed therapeutics [7].…”

Genetic and compound screens uncover factors modulating cancer cell response to indisulam

“…Personalised anti-cancer therapy is limited by high costs of drug development ( Workman et al, 2017 ; Schlander et al, 2021 ). One strategy to lower the costs is to reuse compounds already tested in the clinical setting but that were abandoned because of lack of single agent activity.…”

Global Analysis of Deep Learning Prediction Using Large-Scale In-House Kinome-Wide Profiling Data

“…In the process of drug discovery, a huge number of experiments need to be conducted, making the creation of new drugs expensive and time consuming. 1 In the initial stage of research, hit compounds are obtained by screening hundreds of thousands to millions of compounds. Each pharmaceutical company has a compound library typically featuring a million or more compounds, and the number of compounds currently synthesized commercially is in the hundreds of millions.…”